Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease

Fabry disease results in a global vasculopathy leading to early-onset stroke and renal and cardiac failure. We found that random myeloperoxidase in serum and plasma was significantly elevated in 73 consecutive male patients with Fabry disease. Random serum myeloperoxidase level in men predicted the...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaneski, Christine R. (Author) , Moore, David F. (Author) , Ries, Markus (Author) , Zirzow, G. C. (Author) , Schiffmann, Raphael (Author)
Format: Article (Journal)
Language:English
Published: December 12, 2006
In: Neurology
Year: 2006, Volume: 67, Issue: 11, Pages: 2045-2047
ISSN:1526-632X
DOI:10.1212/01.wnl.0000247278.88077.09
Online Access:Verlag, Volltext: https://doi.org/10.1212/01.wnl.0000247278.88077.09
Verlag, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950664/
Get full text
Author Notes:C.R. Kaneski, MS, D.F. Moore, MD, PhD, DIC, M. Ries, MD, MHSc, G.C. Zirzow, BS, R. Schiffmann, MD, MHSc
Description
Summary:Fabry disease results in a global vasculopathy leading to early-onset stroke and renal and cardiac failure. We found that random myeloperoxidase in serum and plasma was significantly elevated in 73 consecutive male patients with Fabry disease. Random serum myeloperoxidase level in men predicted the risk of a Fabry vasculopathy-related event in subsequent years. Long-term enzyme replacement therapy did not reduce myeloperoxidase level or eliminate the risk of vasculopathic events.
Item Description:Gesehen am 15.05.2019
Physical Description:Online Resource
ISSN:1526-632X
DOI:10.1212/01.wnl.0000247278.88077.09